ClinConnect ClinConnect Logo
Search / Trial NCT06894498

Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss

Launched by BOSTON SCIENTIFIC CORPORATION · Mar 19, 2025

Trial Information

Current as of April 26, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at the long-term effects of a procedure called Endoscopic Sleeve Gastroplasty (ESG) on weight loss. ESG is a minimally invasive treatment that helps people lose weight and improve related health conditions. The study aims to understand how patients who had this procedure more than five years ago have maintained their weight loss and what their journey has been like since then.

To participate, individuals must be at least 18 years old and have a body mass index (BMI) between 30 and 50, which indicates obesity. Participants should have completed at least one follow-up appointment after their ESG procedure, and they must be willing to attend one more appointment for the study. There are no specific exclusions, so if you meet the age and BMI criteria and have kept up with your follow-up visits, you could be eligible. If you join the study, you can expect to share your experiences and have your progress assessed to help researchers understand the long-term benefits of ESG.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subject is ≥ 18 years of age at the time of the ESG procedure
  • Subject with a BMI between 30 kg/m2 and 50 kg/m2, inclusive, at the time of the primary ESG procedure using Overstitch Endoscopic Suturing System
  • Subject completed follow-up 1-year from the ESG procedure for weight loss management
  • Subject completed or is eligible for follow-up 5-years from the ESG procedure for weight loss management (visit can be collected either retrospectively or prospectively)
  • Subject has returned for a minimum of one annual follow-up at the treating site for weight loss management annually between two and four years from the procedure.
  • Subject is willing to complete one prospective visit (5 year or 5+ year, as appropriate)
  • Subject is able to read, understand, and sign a written Informed Consent Form to participate in the study
  • Exclusion Criteria:
  • None

About Boston Scientific Corporation

Boston Scientific Corporation is a global leader in medical device innovation, dedicated to providing solutions that enhance patient care and improve clinical outcomes. With a strong focus on advancing the treatment of various medical conditions, Boston Scientific develops and manufactures a diverse range of products across multiple specialties, including cardiology, urology, and endoscopy. The company is committed to rigorous clinical research and development, ensuring that its devices meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and ongoing investment in technology and education, Boston Scientific strives to deliver breakthrough therapies that address unmet medical needs and empower patients worldwide.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported